Renub Research, June 2011, Pages: 95
of Alzheimer’s Diseasediseases today and by 2050?
- What is the market share accounted by Alzheimer’s disease drugs in the globalmarkets?
- What is the market share accounted by the region in the global
AM Mind Power Solutions, April 2011, Pages: 37
continues to increase. - Three major primary medications on the market for Alzheimerdisease - Aricept, Exelon, and Razadyne are AChE inhibitors, and the fourth medication, Namenda, is a NMDAr antagonist
Koncept Analytics, March 2009, Pages: 25
strategies accordingly. 1. Introduction
Types of Prescription Medications
1.1 Industry Facts
2. Alzheimer Drugs Market
2.1 Worldwide Alzheimer Drug Market
Global Market Value
Growth Rate
Market Value
Global Industry Analysts, Inc., May 2008, Pages: 530
This report analyzes the worldwide markets for Alzheimer’s and Parkinson’s Disease in Millions of US$. The Major product segments Analyzed are Anti-Alzheimer’s Disease Drugs (Cholinesterase
UBM Canon, Aug 2011, Pages: 67
by nervous system diseases, especially Alzheimer's disease, is increasing in frequency. Alzheimer's disease strikes nearly a half million new patients each year. There are only a handful of FDA-approved drugs
Global Industry Analysts, Inc., April 2010, Pages: 1108
This report analyzes the worldwide markets for Neurodegenerative Drugs in US$ Million by the following disease types: AlzheimersDisease, Parkinsons Disease, Multiple Sclerosis, Amyotrophic Lateral
BioPharm Reports (VennBio Ltd.), April 2009, Pages: 110
Overview: Today's armoury of approved drugs for the treatment of Alzheimer's Disease (AD) largely depends on just five therapeutic agents. In 2007, three of these agents represented 88% of global
NeuroInsights, May 2011, Pages +: 500
the dynamics of rapidly changing CNS markets.
The report includes detailed information on products in development globally for over 18 indications at 800 companies including Alzheimer's, addiction, ALS
Global Industry Analysts, Inc., May 2008, Pages: 527
This report analyzes the worldwide markets for CNS Therapeutics in Millions of US$. The specific product Groups analyzed are Anti-Alzheimers, Anti-Parkinsons, Anti-Epilepsy, Pain Management
Business Insights, Jan 2007, Pages: 224
of molecular biological technology in the CNS area are positive, with antibodies for
Alzheimer’s disease beginning to make real progress.
-Companies are moving away from merely treating symptoms to looking
NeuroInsights, May 2010
of rapidly changing CNS markets.
The report includes detailed information on products in development globally for over 18 indications at 800 companies including Alzheimer's, addiction, ALS, anxiety
Frost & Sullivan, Nov 2003
to severe form of AD. The drug could reach blockbuster status faster than Aricept touched $1 billion in sales.
This research examines the U.S. Alzheimer's diseasemedicationmarkets with specific focus
GBI Research, Nov 2011, Pages: 230
therapeutics market.
GBI Research analysis shows that the overall global CNS disorder therapeutics market for the eleven indications that includes Alzheimer’s disease, multiple sclerosis, Parkinson’s disease
Marketstrat, Inc., Jan 2010, Pages: 261
between 2008 and 2016, reaching about $2 billion by the end of 2016. This is despite the fact that the UI market is one of the most underpenetrated medicalmarkets. About 30% of women all over the world
Espicom Business Intelligence Ltd, Nov 2006, Pages: 127
these diseases are likely to become more commonplace due to patient demographics and become a greater burden on health care services.
GlobalAlzheimer’s and Parkinson’s market
In 2005, approximately 45% of AD/PD
UBM Canon, Feb 2011, Pages: 80
/obesity. Recent evidence has shown that some OTC medications can also help fight diseases such as Alzheimer's and Parkinson's, as well as heart attacks and some cancers.
A significant factor driving
NeuroInsights, Aug 2010, Pages: 183
- TABLE: Treatments in Development by Company and Indication
Neurodegenerative Diseases
- Alzheimer's Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease
- Parkinson's Disease and Syndrome
Business Insights, July 2010, Pages: 198
for Alzheimer’s disease diagnosis and treatment monitoring
The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Commercial PET ligands in development for AD diagnosis
Imaging biomarkers for Parkinson
